PH12021551262A1 - Macrocyclic compound and use thereof - Google Patents
Macrocyclic compound and use thereofInfo
- Publication number
- PH12021551262A1 PH12021551262A1 PH12021551262A PH12021551262A PH12021551262A1 PH 12021551262 A1 PH12021551262 A1 PH 12021551262A1 PH 12021551262 A PH12021551262 A PH 12021551262A PH 12021551262 A PH12021551262 A PH 12021551262A PH 12021551262 A1 PH12021551262 A1 PH 12021551262A1
- Authority
- PH
- Philippines
- Prior art keywords
- disease
- kidney
- mitochondrial
- inflammatory
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018228234 | 2018-12-05 | ||
| PCT/JP2019/048593 WO2020116660A1 (en) | 2018-12-05 | 2019-12-04 | Macrocyclic compound and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021551262A1 true PH12021551262A1 (en) | 2021-10-25 |
Family
ID=70975488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021551262A PH12021551262A1 (en) | 2018-12-05 | 2021-05-31 | Macrocyclic compound and use thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11518763B2 (https=) |
| EP (1) | EP3890738A4 (https=) |
| JP (2) | JP2022510736A (https=) |
| KR (1) | KR102919982B1 (https=) |
| CN (1) | CN113164468A (https=) |
| AR (1) | AR117251A1 (https=) |
| AU (1) | AU2019391942B2 (https=) |
| BR (1) | BR112021010704A2 (https=) |
| CA (1) | CA3121952C (https=) |
| CL (1) | CL2021001451A1 (https=) |
| CO (1) | CO2021007304A2 (https=) |
| MX (1) | MX2021006527A (https=) |
| NZ (1) | NZ776102A (https=) |
| PH (1) | PH12021551262A1 (https=) |
| SG (1) | SG11202105125XA (https=) |
| TW (1) | TWI820266B (https=) |
| UA (1) | UA127872C2 (https=) |
| WO (1) | WO2020116660A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE065501T2 (hu) | 2018-08-20 | 2024-05-28 | Janssen Pharmaceutica Nv | A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok |
| MX2021014680A (es) | 2019-05-31 | 2022-04-06 | Ube Corp | Derivado de benzotriazol. |
| WO2022056448A1 (en) * | 2020-09-14 | 2022-03-17 | Sanofi | Tetrahydroisoquinoline derivatives for the treatment of red blood disorders and inflammatory diseases |
| EP4688779A2 (en) * | 2023-04-03 | 2026-02-11 | Acelink Therapeutics, Inc. | Novel compounds and uses thereof |
| CN119707895B (zh) * | 2023-12-18 | 2026-03-31 | 江苏苏中药业研究院有限公司 | 一种7-甲酰基-2,3-二氢苯并呋喃-4-碳腈的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011298091B2 (en) | 2010-08-31 | 2015-08-20 | Accure Therapeutics, S.L. | Agonists of neurotrophin receptors and their use as medicaments |
| ME03421B (me) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba |
| KR102301867B1 (ko) * | 2013-12-18 | 2021-09-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| EP3766878B1 (en) | 2015-06-15 | 2022-03-16 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| SI3782996T1 (sl) | 2015-06-15 | 2024-06-28 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulatorji |
| CA2988373A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| US10201531B2 (en) | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| WO2017060855A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| EP3551621A1 (en) | 2016-12-12 | 2019-10-16 | GlaxoSmithKline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| WO2018109641A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
| JP2020502136A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのビスアリールアミド |
| JP2020502123A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしてのビスアリール複素環 |
| EP3555068B1 (en) | 2016-12-14 | 2020-12-02 | GlaxoSmithKline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
| US11059816B2 (en) | 2016-12-15 | 2021-07-13 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as NRF2 activators |
| CA3044773A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activators |
| AR110590A1 (es) | 2016-12-27 | 2019-04-10 | Biogen Ma Inc | Activador de nrf2 |
| US20190389836A1 (en) * | 2017-01-30 | 2019-12-26 | Biogen Ma Inc. | Nrf2 activator |
| WO2018140738A1 (en) | 2017-01-30 | 2018-08-02 | Biogen Ma Inc. | Nrf 2 activator |
| JP2020097526A (ja) | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
-
2019
- 2019-12-04 NZ NZ776102A patent/NZ776102A/en unknown
- 2019-12-04 EP EP19892751.9A patent/EP3890738A4/en active Pending
- 2019-12-04 CN CN201980080214.5A patent/CN113164468A/zh active Pending
- 2019-12-04 AR ARP190103549A patent/AR117251A1/es unknown
- 2019-12-04 US US17/299,659 patent/US11518763B2/en active Active
- 2019-12-04 WO PCT/JP2019/048593 patent/WO2020116660A1/en not_active Ceased
- 2019-12-04 AU AU2019391942A patent/AU2019391942B2/en active Active
- 2019-12-04 TW TW108144324A patent/TWI820266B/zh active
- 2019-12-04 KR KR1020217020790A patent/KR102919982B1/ko active Active
- 2019-12-04 BR BR112021010704-5A patent/BR112021010704A2/pt unknown
- 2019-12-04 UA UAA202102856A patent/UA127872C2/uk unknown
- 2019-12-04 SG SG11202105125XA patent/SG11202105125XA/en unknown
- 2019-12-04 JP JP2021554804A patent/JP2022510736A/ja active Pending
- 2019-12-04 CA CA3121952A patent/CA3121952C/en active Active
- 2019-12-04 MX MX2021006527A patent/MX2021006527A/es unknown
-
2021
- 2021-05-31 PH PH12021551262A patent/PH12021551262A1/en unknown
- 2021-06-02 CL CL2021001451A patent/CL2021001451A1/es unknown
- 2021-06-03 CO CONC2021/0007304A patent/CO2021007304A2/es unknown
-
2024
- 2024-06-25 JP JP2024102161A patent/JP2024123202A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3121952C (en) | 2025-05-13 |
| TWI820266B (zh) | 2023-11-01 |
| WO2020116660A1 (en) | 2020-06-11 |
| AU2019391942A1 (en) | 2021-06-03 |
| MX2021006527A (es) | 2021-07-21 |
| EP3890738A4 (en) | 2022-08-17 |
| EP3890738A1 (en) | 2021-10-13 |
| CL2021001451A1 (es) | 2021-12-24 |
| SG11202105125XA (en) | 2021-06-29 |
| KR102919982B1 (ko) | 2026-02-02 |
| US20220119391A1 (en) | 2022-04-21 |
| AR117251A1 (es) | 2021-07-21 |
| JP2022510736A (ja) | 2022-01-27 |
| TW202039494A (zh) | 2020-11-01 |
| CA3121952A1 (en) | 2020-06-11 |
| BR112021010704A2 (pt) | 2021-08-24 |
| CN113164468A (zh) | 2021-07-23 |
| US11518763B2 (en) | 2022-12-06 |
| KR20210099622A (ko) | 2021-08-12 |
| NZ776102A (en) | 2024-12-20 |
| JP2024123202A (ja) | 2024-09-10 |
| CO2021007304A2 (es) | 2021-06-21 |
| AU2019391942B2 (en) | 2024-03-21 |
| UA127872C2 (uk) | 2024-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551262A1 (en) | Macrocyclic compound and use thereof | |
| CY1118574T1 (el) | Ενωσεις υποκατεστημενου πυριδινο-2-καρβοξαμιδιου ως αναστολεις κινασης ρυθμισης σηματος αποπτωσης | |
| CR20210085A (es) | Compuestos de 2,6-diaminopiridina | |
| PH12015502012A1 (en) | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | |
| MX2012015105A (es) | Inhibidores de cinasa de regulacion mediante señal de apoptosis. | |
| SG10201902370QA (en) | Compositions and methods of use of phorbol esters | |
| MD20160069A2 (ro) | Inhibitor al kinazei inductoare de apoptoză | |
| MX2010003603A (es) | Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida. | |
| JOP20210329A1 (ar) | مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز | |
| PH12018500261A1 (en) | Azole benzene derivative | |
| GEP20207095B (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| MX361925B (es) | Medicamento inhalable que comprende tiotropio. | |
| SA515360085B1 (ar) | مشتق ودواء بيريدين | |
| PH12015502264A1 (en) | Pyrazole derivative | |
| NZ590454A (en) | Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology | |
| MX2022004744A (es) | Composiciones que comprenden 2'-fucosil-lactosa para prevenir el asma. | |
| IN2014DN00185A (https=) | ||
| Hansbro et al. | A short-term model of COPD identifies a role for mast cell tryptase | |
| Althaqfi et al. | Results of brachytherapy in anal cancer from a cohort of 173 patients treated at the same institution over a 20 year period | |
| WO2014176510A3 (en) | N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino) naphthalen-1(4h)-ylidene)-n-methylmethanaminium, derivatives, and their use in treating cancer | |
| Levina et al. | Risk factors of development of endothelium dysfunctions at smokers | |
| Bouyssou et al. | Late asthmatic response is modulated by TRPA1 antagonists in ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs | |
| Paralija et al. | Clinical features of pulmonary tuberculosis in patients with diabetes mellitus | |
| Rajaram et al. | C71 CRYSTAL BALL: CLINICAL FEATURES OF PULMONARY VASCULAR DISEASE II: A Survey Of Treatment And Listing Patterns Of Patients With Pulmonary Hypertension For Liver Transplantation | |
| Dean et al. | A52 PRECLINICAL TRIALS IN PULMONARY HYPERTENSION MODELS: NOVEL TARGETS AND DELIVERY: Effect Of Metformin On Pulmonary Hypertension In The Sugen/hypoxic Rat Model: Possible Role For Aromatase |